Sign up to save your podcasts
Or
Share Breathwork: Sarcoidosis with Professor Anthony O'Regan (Part 2)
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Breathwork: Sarcoidosis with Professor Anthony O'Regan (Part 2)
In this episode, we delve into sarcoidosis with Professor Anthony O'Regan. We discuss the nuances of diagnosing sarcoidosis and revisit the pathophysiology of the condition. This episodes details the importance of follow up care and provides insights into how to tease out differentials. Furthermore, we address how to determine which patients should be treated, along with choice of treatments and duration.
00:15 Rapid fire round: sarcoidosis
00:45 Pathophysiology of sarcoidosis
05:30 Multisystem involvement in sarcoidosis
07:15 Granulomatous disease
09:00 Referral to respiratory clinic (Symptoms/Differentials/Family history/Travel)
10:30 Initial investigations
10:45 Coming to a diagnosis of sarcoidosis
14:05 The role of biopsy in diagnosis of sarcoidosis
15:50 Teasing out the differentials in follow up
17:35 When to treat in sarcoidosis
19:25 Duration of treatment
19:50 Relapse of disease
21:00 Starting dose of steroids
22:00 Disease modifying therapy
23:30 Antifibrotics
24:25 Follow up in sarcoidosis
25:01 The future of sarcoidosis
Show Notes:
- Judson MA, Baughman RP, Teirstein AS, Terrin ML, Yeager H Jr. Defining organ involvement in sarcoidosis: the ACCESS proposed instrument. ACCESS Research Group. A Case Control Etiologic Study of Sarcoidosis. Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG. 1999 Mar;16(1):75-86. PMID: 10207945.
- 40 consecutive patients in Ireland
20% end up on steroids
- John Gibson study on steroids RCT
Gibson GJ, Prescott RJ, Muers MF, Middleton WG, Mitchell DN, Connolly CK. "British Thoracic Society Sarcoidosis study: effects of long-term corticosteroid treatment." Thorax. 1996;51(3):238-247. DOI: 10.1136/thx.51.3.238
- Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial Wells, Athol UAbe, S. et al. The Lancet Respiratory Medicine, Volume 8, Issue 5, 453 – 460
- ITS Flashcard Sarcoidosis https://irishthoracicsociety.com/wp-content/uploads/2022/02/15.-Sarcoidosis-30.11.21.pdf
View all episodes
By The Podcast StudiosIn this episode, we delve into sarcoidosis with Professor Anthony O'Regan. We discuss the nuances of diagnosing sarcoidosis and revisit the pathophysiology of the condition. This episodes details the importance of follow up care and provides insights into how to tease out differentials. Furthermore, we address how to determine which patients should be treated, along with choice of treatments and duration.
00:15 Rapid fire round: sarcoidosis
00:45 Pathophysiology of sarcoidosis
05:30 Multisystem involvement in sarcoidosis
07:15 Granulomatous disease
09:00 Referral to respiratory clinic (Symptoms/Differentials/Family history/Travel)
10:30 Initial investigations
10:45 Coming to a diagnosis of sarcoidosis
14:05 The role of biopsy in diagnosis of sarcoidosis
15:50 Teasing out the differentials in follow up
17:35 When to treat in sarcoidosis
19:25 Duration of treatment
19:50 Relapse of disease
21:00 Starting dose of steroids
22:00 Disease modifying therapy
23:30 Antifibrotics
24:25 Follow up in sarcoidosis
25:01 The future of sarcoidosis
Show Notes:
- Judson MA, Baughman RP, Teirstein AS, Terrin ML, Yeager H Jr. Defining organ involvement in sarcoidosis: the ACCESS proposed instrument. ACCESS Research Group. A Case Control Etiologic Study of Sarcoidosis. Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG. 1999 Mar;16(1):75-86. PMID: 10207945.
- 40 consecutive patients in Ireland
20% end up on steroids
- John Gibson study on steroids RCT
Gibson GJ, Prescott RJ, Muers MF, Middleton WG, Mitchell DN, Connolly CK. "British Thoracic Society Sarcoidosis study: effects of long-term corticosteroid treatment." Thorax. 1996;51(3):238-247. DOI: 10.1136/thx.51.3.238
- Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial Wells, Athol UAbe, S. et al. The Lancet Respiratory Medicine, Volume 8, Issue 5, 453 – 460
- ITS Flashcard Sarcoidosis https://irishthoracicsociety.com/wp-content/uploads/2022/02/15.-Sarcoidosis-30.11.21.pdf